Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 1022, Issue , 2016, Pages 290-297

  Poinsignon, Vianney ^a   Mercier, Lionel ^a   Nakabayashi, Koïchi ^b   David, Muriel D ^b   Lalli, Alexandre ^a   Penard Lacronique, Virginie ^b   Quivoron, Cyril ^b   Saada, Véronique ^b   De Botton, Stéphane ^b   Broutin, Sophie ^a   Paci, Angelo ^a,c,d  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d CNRS   (France)

Author keywords

2 Hydroxyglutaric acid; Biomarker; Endogenous compounds; Isocitrate dehydrogenase mutations; Liquid tandem mass spectrometry; Oncometabolite

Indexed keywords

BIOMARKERS; BLOOD; DIAGNOSIS; ELECTROSPRAY IONIZATION; ENANTIOMERS; LIQUIDS; MASS SPECTROMETRY; METABOLISM; PHASE SEPARATION; SPECTROMETRY;

CHIRAL STATIONARY PHASE; ELECTROSPRAY IONIZATION (ESI); ENDOGENOUS COMPOUND; ISOCITRATE DEHYDROGENASE; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; ONCOMETABOLITE; PROGNOSTIC SIGNIFICANCE; TANDEM MASS SPECTROMETRY;

LIQUID CHROMATOGRAPHY;

2 HYDROXYGLUTARIC ACID; BIOLOGICAL MARKER; ISOCITRATE DEHYDROGENASE; ALPHA-HYDROXYGLUTARATE; GLUTARIC ACID DERIVATIVE; TUMOR MARKER;

ACCURACY; ACUTE MYELOBLASTIC LEUKEMIA; ARTICLE; BLOOD SAMPLING; BODY FLUID; CELL METABOLISM; CONTROLLED STUDY; CORRELATION COEFFICIENT; DERIVATIZATION; DIASTEREOISOMER; DILUTION; ELECTROSPRAY; ENANTIOMER; HUMAN; HUMAN CELL; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SOLID PHASE EXTRACTION; STANDARD; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ACUTE MYELOID LEUKEMIA; BLOOD; CHEMISTRY; LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STEREOISOMERISM; TUMOR CELL LINE;

BIOMARKERS, TUMOR; CELL LINE, TUMOR; CHROMATOGRAPHY, LIQUID; GLUTARATES; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; LINEAR MODELS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 84964461711     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2016.04.030     Document Type: Article

References (36)

1. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674. 10.1016/j.cell.2011.02.013.
2. Wallace D.C. Mitochondria and cancer. Nat. Rev. Cancer 2012, 12:685-698. 10.1038/nrc3365.
3. McKenney A.S., Levine R.L. Isocitrate dehydrogenase mutations in leukemia. J. Clin. Investig. 2013, 123:3672-3677. 10.1172/JCI67266.
4. Yang H., Ye D., Guan K.-L., Xiong Y. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin. Cancer Res. 2012, 18:5562-5571. (CCR- 12-1773). 10.1158/1078-0432.
5. Engqvist M.K.M., Eßer C., Maier A., Lercher M.J., Maurino V.G. Mitochondrial 2-hydroxyglutarate metabolism. Mitochondrion 2014, 19(Pt B):275-281. 10.1016/j.mito.2014.02.009.
6. Dang L., White D.W., Gross S., Bennett B.D., Bittinger M.A., Driggers E.M., et al. Cancer- associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009, 462:739-744. 10.1038/nature08617.
7. Parker S.J., Metallo C.M. Metabolic consequences of oncogenic IDH mutations. Pharmacol. Ther. 2015, 152:54-62. 10.1016/j.pharmthera.2015.05.003.
8. Cairns R.A., Harris I.S., Mak T.W. Regulation of cancer cell metabolism. Nat. Rev. Cancer. 2011, 11:85-95. 10.1038/nrc2981.
9. Sjöblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006, 314:268-274. 10.1126/science.1133427.
10. Parsons D.W., Jones S., Zhang X., Lin J.C.-H., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812. 10.1126/science.1164382.
11. Reitman Z.J., Yan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J. Natl. Cancer Inst. 2010, 102:932-941. 10.1093/jnci/djq187.
12. Cairns R.A., Mak T.W. Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. Cancer Discov. 2013, 3:730-741. (CD-13- 0083). 10.1158/2159-8290.
13. Lu C., Ward P.S., Kapoor G.S., Rohle D., Turcan S., Abdel-Wahab O., et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012, 483:474-478. 10.1038/nature10860.
14. Figueroa M.E., Abdel-Wahab O., Lu C., Ward P.S., Patel J., Shih A., et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010, 18:553-567. 10.1016/j.ccr.2010.11.015.
15. Kranendijk M., Struys E.A., Salomons G.S., Van der Knaap M.S., Jakobs C. Progress in understanding 2-hydroxyglutaric acidurias. J. Inherit. Metab. Dis. 2012, 35:571-587. 10.1007/s10545-012-9462-5.
16. Janin M., Mylonas E., Saada V., Micol J.-B., Renneville A., Quivoron C., et al. Serum 2- hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. J. Clin. Oncol. 2014, 32:297-305. 10.1200/JCO.2013.50.2047.
17. Borger D.R., Goyal L., Yau T., Poon R.T., Ancukiewicz M., Deshpande V., et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase- mutant intrahepatic cholangiocarcinoma. Clin. Cancer Res. 2014, 20:1884-1890. 10.1158/1078-0432.CCR- 13-2649.
18. Kamerling J.P., Duran M., Gerwig G.J., Ketting D., Bruinvis L., Vliegenthart J.F., et al. Determination of the absolute configuration of some biologically important urinary 2- hydroxydicarboxylic acids by capillary gas-liquid chromatography. J. Chromatogr. 1981, 222:276-283. (accessed 26.10.15). http://www.ncbi.nlm.nih.gov/pubmed/6788787.
19. Gibson K.M., ten Brink H.J., Schor D.S., Kok R.M., Bootsma A.H., Hoffmann G.F., et al. Stable- isotope dilution analysis of d- and l-2- hydroxyglutaric acid: application to the detection and prenatal diagnosis of d- and l-2-hydroxyglutaric acidemias. Pediatr. Res. 1993, 34:277-280. 10.1203/00006450-199309000-00007.
20. Sellner L., Capper D., Meyer J., Langhans C.-D., Hartog C.-M., Pfeifer H., et al. Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations. Eur. J. Haematol. 2010, 85:457-459. 10.1111/j.1600- 0609.2010.01505.x.
21. Ward P.S., Patel J., Wise D.R., Abdel- Wahab O., Bennett B.D., Coller H.A., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha- ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010, 17:225-234. 10.1016/j.ccr.2010.01.020.
22. Capper D., Simon M., Langhans C.-D., Okun J.G., Tonn J.C., Weller M., et al. 2- Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size. Int. J. Cancer. 2012, 131:766-768. 10.1002/ijc.26425.
23. Chalmers R.A., Lawson A.M., Watts R.W.E., Tavill A.S., Kamerling J.P., Hey E., et al. d-2-Hydroxyglutaric aciduria: case report and biochemical studies. J. Inherit. Metab. Dis. 1980, 3:11-15. 10.1007/BF02312516.
24. Oldham W.M., Clish C.B., Yang Y., Loscalzo J. Hypoxia-mediated increases in l-2-hydroxyglutarate coordinate the metabolic response to reductive stress. Cell Metab. 2015, 22:291-303. 10.1016/j.cmet.2015.06.021.
25. Intlekofer A.M., Dematteo R.G., Venneti S., Finley L.W.S., Lu C., Judkins A.R., et al. Hypoxia induces production of l-2-hydroxyglutarate. Cell Metab. 2015, 22:304-311. 10.1016/j.cmet.2015.06.023.
26. Losman J.-A., Looper R.E., Koivunen P., Lee S., Schneider R.K., McMahon C., et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 2013, 339:1621-1625. 10.1126/science.1231677.
27. Shim E.-H., Livi C.B., Rakheja D., Tan J., Benson D., Parekh V., et al. l-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014, 4:1290-1298. (CD-13-0696). 10.1158/2159-8290.
28. Koivunen P., Lee S., Duncan C.G., Lopez G., Lu G., Ramkissoon S., et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 2012, 483:484-488. 10.1038/nature10898.
29. European Medicines Agency Guideline Bioanalytical Method Validation-WC500109686 2011, http://ww w.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf (accessed 26.10.15).
30. Duran M., Kamerling J.P., Bakker H.D., van Gennip A.H., Wadman S.K. l-2- Hydroxyglutaric aciduria: an inborn error of metabolism?. J. Inherit. Metab. Dis. 1980, 3:109-112.
31. Rakheja D., Fuda F., Vandergriff T., Boriack R., Medeiros B.C., Frankel A.E., et al. Increased plasma d-2-hydroxyglutarate in isocitrate dehydrogenase 2-mutated blastic plasmacytoid dendritic cell neoplasm. Hum. Pathol. 2015, 46:322-326. 10.1016/j.humpath.2014.10.013.
32. Shim E.-H., Livi C.B., Rakheja D., Tan J., Benson D., Parekh V., et al. l-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer. Cancer Discov. 2014, 4:1290-1298. (CD-13-0696). 10.1158/2159-8290.
33. Struys E.A., Jansen E.E.W., Verhoeven N.M., Jakobs C. Measurement of urinary d- and l-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-l-tartaric anhydride. Clin. Chem. 2004, 50:1391-1395. 10.1373/clinchem.2004.033399.
34. Tan B., Lu Z., Dong S., Zhao G., Kuo M.-S. Derivatization of the tricarboxylic acid intermediates with O-benzylhydroxylamine for liquid chromatography-tandem mass spectrometry detection. Anal. Biochem. 2014, 465:134-147. 10.1016/j.ab.2014.07.027.
35. Cheng Q.-Y., Xiong J., Huang W., Ma Q., Ci W., Feng Y.-Q., et al. Sensitive determination of onco-metabolites of d- and l-2-hydroxyglutarate enantiomers by chiral derivatization combined with liquid chromatography/mass spectrometry analysis. Sci. Rep. 2015, 5:15217. 10.1038/srep15217.
36. Terunuma A., Putluri N., Mishra P., Mathé E.A., Dorsey T.H., Yi M., et al. MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J. Clin. Investig. 2014, 124:398-412. 10.1172/JCI71180.